The guidance does not include patients with highly active MS. The guidance published by the SMC represents an important step in improving the standard of care available to people with MS.
Aubagio is the first medicine in Genzyme’s pipeline of MS therapies to receive final SMC guidance and become available to patients in Scotland.
Genzyme UK and Ireland general manager Brendan Martin noted this is a very exciting time and the launch of Aubagio represents an important milestone for Genzyme as the company provides new options to the MS community.
"Our commitment to improving the lives of people with MS goes beyond advancing treatment options, and we have a patient support programme underway to further support patients with adherence," Martin added.